Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지

Valproate-associated weight gain and potential predictors in children with epilepsy

Valproate 치료를 받는 간질환아에서 체중증가와 영향을 주는 인자

  • Jang, Gook Chan (Department of Pediatrics, College of Medicine, Chosun University) ;
  • Kim, Eun Young (Department of Pediatrics, College of Medicine, Chosun University) ;
  • Rho, Young Il (Department of Pediatrics, College of Medicine, Chosun University) ;
  • Moon, Kyung Rye (Department of Pediatrics, College of Medicine, Chosun University) ;
  • Park, Sang Kee (Department of Pediatrics, College of Medicine, Chosun University)
  • 장국찬 (조선대학교 의과대학 소아과학교실) ;
  • 김은영 (조선대학교 의과대학 소아과학교실) ;
  • 노영일 (조선대학교 의과대학 소아과학교실) ;
  • 문경래 (조선대학교 의과대학 소아과학교실) ;
  • 박상기 (조선대학교 의과대학 소아과학교실)
  • Received : 2007.03.11
  • Accepted : 2007.04.15
  • Published : 2007.05.15
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose : The purpose of this study was to determine the incidence and potential predictors of weight gain in older children and teens treated with valproate (VPA) for epilepsy. Methods : Sixty-five subjects aged 8 to 17 years of age, who began VPA treatment between January 1, 2001, and December 31, 2004, and who had documented weight and height measurements at medication initiation and at least one follow-up visit were retrospectively identified. Exclusion criteria were follow-up <6 months, discontinuation of VPA within 6 months, and concurrent therapy with medication known to affect weight (such as topiramate, carbamazepin). Body mass index (BMI) was calculated at initiation and either discontinuation of VPA or last follow-up and stratified into four categories: group 1, underweight <5%; group 2, appropriate 5-85%; group 3, potentially overweight 85-95%; group 4, overweight >95%. Results : Twenty-eight subjects (77.8%) remained within their same category and eight (22.2%) moved up at least one category. Weight gain (increase in BMI difference) was observed in 72.2% of the 36 subjects treated with VPA. Three factors, neurocognitive status (P=0.017), seizure type (P=0.001) and duration of VPA treatment (P=0.035) were identified to be significant predictors of BMI difference. Conclusion : VPA induces weight gain in children and teens with epilepsy. These factors which are normal neurocognitive status, primary generalized type and duration of VPA treatment over the 12 months were predictors for an increase of weight gain. Therefore potential weight gain should be discussed with patients before the initiation of therapy and BMI should be monitored closely.

목 적 : VPA치료를 받는 소아 청소년기 간질환자들에서 체중증가의 비율과 체중증가에 관련되는 예측 인자를 알아보고자 하였다. 방 법 : 2001년 1월 1일부터 2004년 12월 31일까지 VPA 치료를 받기 시작한 8세에서 17세까지의 환아를 대상으로 하였다. 제외기준은 치료 시작후 6개월 이내 치료가 중단된 경우, 체중에 영향을 주는 약물을 병합한 경우 등이었다. VPA 치료 시작시와 치료 시작 후 한번이상 재방문시에 체중과 신장이 측정되어 두 시점에서 BMI를 측정한 후 대상 환아들을 백분위수에 따라 4가지의 BMI군으로 분류하여 BMI군의 상승여부를 조사했으며 체중증가율을 의미하는 BMI difference를 계산하였다. 또한 체중증가에 영향을 미치는 여러 인자들을 회귀분석 하였다. 결 과 : 전체 36명중 총 8명의 환아가 VPA 치료전보다 최소 한 단계 이상의 BMI군의 상승변화를 보였으며 대상환아의 72.2%에서 체중증가(BMI difference의 증가)를 나타내었다. 신경정신 발달(P=0.017), 간질 형태(P=0.001), 투약기간(P=0.035)은 통계적으로 유의한 체중증가에 영향을 미치는 예측인자였다. 결 론 : VPA는 간질 환아에서 체중증가를 유발하며 정상 신경정신 발달, 전신 발작형 간질, 12개월 이상의 투약기간이 체중증가의 예측인자로 생각된다. 따라서 VPA 치료를 받는 소아 간질환자에서는 치료 시작 전에 VPA로 인한 체중증가의 가능성을 고려하여 치료 받는 중 BMI의 지속적인 감시측정이 필요할 것으로 생각된다.

Keywords

Acknowledgement

Supported by : 조선대학교

References

  1. Kim SJ, Park HS, Hwang JS, Jung YJ, Ko TS. Change of body weight according to antiepileptic drugs in children with epilepsy: Valproic Acid vs. Topiramate. J Korean Child Neurol Soc 2003;11;68-72
  2. Dinesen H, Gram L, Andersen T, Dam M. Weight gain during treatment with valproate. Acta Neurol Scand 1984; 70:65-9
  3. Corman CL, Leung NM, Guberman AH. Weight gain in epileptic patients during treatment with valproic acid: A retrospective study. Can J Neurol Sci 1997;24:240-4 https://doi.org/10.1017/S0317167100021879
  4. Biton V, Mirza W, Montouris G, Vuong A, Hammer AE, Barrett PS. Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology 2001;56:172-7 https://doi.org/10.1212/WNL.56.2.172
  5. Egger J, Brett EM. Effects of sodium valproate in 100 children with special reference to weight. BMJ 1981; 283:577-81 https://doi.org/10.1136/bmj.283.6291.577
  6. Isojarvi JI, Rattya J, Myllyla VV, Knip M, Koivunen R, Pakarinen AJ, Tekay A, Tapanainen JS. Valproate, lamotrigen, and insulin-mediated risks in women with epilepsy. Ann Neurol 1998;43:446-51 https://doi.org/10.1002/ana.410430406
  7. Considine RV, Sinha MK, Heiman ML. Serum immunoreactive leptin concentrations in normal-weight and obese humans. N Engl J Med 1996;34:292-5
  8. Maffei M, Halaas J, Ravussin E. Leptin level is human and Rodent: measurement of plasma leptin and ob gene RNA in obese and weight-reduced subjects. Nat Med 1995;1:1155- 61 https://doi.org/10.1038/nm1195-1155
  9. Demir E, Aysun S. Weight gain associated with valproate in children. Pediatr Neurol 2000;22:361-4 https://doi.org/10.1016/S0887-8994(00)00133-8
  10. Isojarvi JIT, Laatikainen TJ, Knip M, Pakarinen AJ, Juntunen KTS, Myllyla VV. Obesity and endocrine disorders in women taking valproate for epilepsy. Ann Neurol 1996; 39:579-84 https://doi.org/10.1002/ana.410390506
  11. Wirrell EC. Valproic acid-associated weight gain in older children and teens with epilepsy. Pediatr Neurol 2003;28: 126-9 https://doi.org/10.1016/S0887-8994(02)00505-2
  12. Kim IC, Kim ES, Bae EJ, Park WI, Lee HG, Lee KJ. The pattern of weight gain and change of peripheral serum lipid profiles in idiopathic epileptic children treated with valproate. J Korean Child Neurol Soc 2002;10:81-6
  13. Wirrell EC, Camfield CS, Camfield PR, Dooley JM, Gordon KE, Smith B. Long-term psychosocial outcome in typical absence epilepsy: Sometimes a wolf in sheeps' clothing. Arch Pediatr Adolesc Med 1997;151:152-8 https://doi.org/10.1001/archpedi.1997.02170390042008
  14. Austin JK, Smith MS, Risinger MW, McNelis AM. Childhood epilepsy and asthma: Comparison of quality of life. Epilepsia 1994;35:608-15 https://doi.org/10.1111/j.1528-1157.1994.tb02481.x
  15. Turnbull DM, Dick DJ, Wilson L, Sherratt HS, Alberti KG. Valproate causes metabolic disturbance in normal man. J Neurol Neurosurg Psychiatry 1986;49:405-10 https://doi.org/10.1136/jnnp.49.4.405
  16. Rogers V, Vandenberghe Y, Vercruysse A. Inhibition of gluconeogenesis by so dium valproate and its metabolites in rat hepatocytes. Xenobiotica 1985;15:759-65 https://doi.org/10.3109/00498258509047438
  17. Breum L, Astrup A, Gram L. Metabolic changes during treatment with valproate in humans: Implication for untoward weight gain. Metabolism 1992;41:S29-37
  18. Panksepp J, Meeker RB. The role of GABA in the ventro medical hypothalamic regulation of food intake. Brain Res Bull 1980;5:453-60 https://doi.org/10.1016/0361-9230(80)90072-6
  19. Dornhorst A, Jenkins JS. The evaluation of sodium valproate treatment of Nelson's syndrome. J Clin Endocrinol Metab 1983;56:985-91 https://doi.org/10.1210/jcem-56-5-985
  20. Astrup AV. Sodium valproate promotes obesity by reducing energy expenditure. Int J Obesity 1983;13:126
  21. Vorum H, Gram L, Honore B. Valproate and palmitate binding to serum albumin in valproate-treated patients: Relation to obesity. Epilepsy Res 1993;16:55-64 https://doi.org/10.1016/0920-1211(93)90040-E
  22. Verrotti A, Basciani F, Moresi S, de Martino M, Morgese G, Hiarelli F. Serum leptin changes in epileptic patients who gain weight after therapy with valproic acid. Neurology 1999;53:230-2 https://doi.org/10.1212/WNL.53.1.230
  23. Shoenfeld WN, Warden CH. Pediatric obesity. An overview of etiology and treatment. Pediatric Clin North Am 1997;44; 339-61 https://doi.org/10.1016/S0031-3955(05)70480-6
  24. Yoon WS, Ryu NE, Woo YJ. Serum leptin levels in epileptic children with anticonvulsant medication. J Korean Child Neurol Soc 1999;6:285-9